MOORESTOWN, N.J., Sept. 16, 2021 /PRNewswire/ -- Tabula Rasa
HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), a
leading healthcare technology company advancing the safe use of
medications, today announced the results of a three-part clinical
study that further demonstrates the strong associations between a
high MedWise Risk Score™ and poor health outcomes.
These studies validate that medication interventions informed by
MedWise® clinical decision support tools improve
health outcomes and lower healthcare costs when used by specially
certified pharmacists.
New Studies prove link between TRHC's MedWise and better health
outcomes, reduced healthcare costs
The peer-reviewed three-part series, Innovative Enhanced
Medication Therapy Management Model: Medication Risk Score,
Medication Safety Review, and Health Care Outcomes, was published
in the September issue of The American Journal of Managed
Care®. In the first study, researchers added to the
body of research showing additional associations between a high
MedWise Risk Score and poor health outcomes. In the second study,
they showed how interventions developed using MedWise by Certified
MedWise Advisor pharmacists reduced medication-related risk and
improved health outcomes. The third study revealed the types and
extent of outcomes that were improved, including reduced costs,
hospitalizations, emergency room visits, and premature death.
"This advanced research adds to the growing body of scientific
study irrefutably demonstrating the unique value that TRHC's
innovative MedWise Science brings to older adults and to Enhanced
Medication Therapy Management (EMTM)," said TRHC Chairman and CEO
Calvin H. Knowlton, PhD. "These
studies clearly show that when pharmacists use the MedWise Risk
Score to prioritize at-risk patients and then use Certified MedWise
Advisor pharmacists to inform interventions, they improve outcomes
and decrease costs."
TRHC's innovative MedWise technology can identify medication
risk for individual patients or across patient populations by
combining patient-specific clinical information, their
pharmacist-reconciled medication regimen, and MedWise Science to
identify which patients and populations are at higher risk for ADEs
and require more immediate medication management attention.
"Today's aging population and rising healthcare costs require
innovative approaches that consider the implications of multi-drug
interactions in patients," said Jacques
Turgeon, BPharm, PhD, TRHC Chief Scientific Officer and CEO
of Precision Pharmacotherapy Research and Development Institute.
"This research is a significant step forward in definitively
demonstrating the value of TRHC's approach as it relates to patient
outcomes."
Previous peer-reviewed, published studies have found that a
lower MedWise Risk Score™ correlated with fewer ADEs, emergency
department visits, and hospitalizations, along with lower medical
costs and a decreased risk of premature death.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) (NASDAQ: TRHC) provides medication
safety solutions that empower healthcare professionals and
consumers to optimize medication regimens, combatting medication
overload and reducing adverse drug events – the fourth leading
cause of death in the US. TRHC's proprietary technology solutions,
including MedWise®, improve patient outcomes, reduce
hospitalizations, and lower healthcare costs. TRHC's extensive
clinical tele-pharmacy network improves care for patients
nationwide. Its solutions are trusted by health plans and
pharmacies to help drive value-based care. For more information,
visit TRHC.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-studies-prove-direct-link-between-medwise-and-better-health-outcomes-including-reduced-healthcare-costs-301378993.html
SOURCE Tabula Rasa HealthCare, Inc.